A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens

A key aspect to finding an efficacious human immunodeficiency virus (HIV) vaccine is the optimization of vaccine schedules that can mediate the efficient maturation of protective immune responses. In the present study, we investigated the effect of alternate booster regimens on the immune responses to a candidate HIV-1 clade C CN54gp140 envelope protein, which was coadministered with the TLR4-agonist glucopyranosyl lipid A-aqueous formulation. Twelve study participants received a common three-dose intramuscular priming series followed by a final booster at either 6 or 12 months. The two homologous prime-boost regimens were well tolerated and induced CN54gp140-specific responses that were observed in both the systemic and mucosal compartments. Levels of vaccine-induced IgG-subclass antibodies correlated significantly with FcγR engagement, and both vaccine regimens were associated with strikingly similar patterns in antibody titer and FcγR-binding profiles. In both groups, identical changes in the antigen (Ag)-specific IgG-subclass fingerprint, leading to a decrease in IgG1 and an increase in IgG4 levels, were modulated by booster injections. Here, the dissection of immune profiles further supports the notion that prime-boost strategies are essential for the induction of diverse Ag-specific HIV-1 responses. The results reported here clearly demonstrate that identical responses were effectively and safely induced by both vaccine regimens, indicating that an accelerated 6-month regimen could be employed for the rapid induction of immune responses against CN54gp140 with no apparent impact on the overall quality of the induced immune response. (This study has been registered at http://ClinicalTrials.gov under registration no. NCT01966900.)

[1]  S. McCormack,et al.  A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes , 2017, Front. Immunol..

[2]  S. Crotty,et al.  Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem , 2017, Immunological reviews.

[3]  Jennifer S. Wood,et al.  Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. , 2016, Cell reports.

[4]  T. Strutt,et al.  Short-Lived Antigen Recognition but Not Viral Infection at a Defined Checkpoint Programs Effector CD4 T Cells To Become Protective Memory , 2016, The Journal of Immunology.

[5]  Peter J. Hogarth,et al.  Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG , 2016, The Journal of Immunology.

[6]  Cornelia L Dekker,et al.  Lineage tracing of human B cells reveals the in vivo landscape of human antibody class switching , 2016, eLife.

[7]  Gretchen A. Stevens,et al.  A century of trends in adult human height , 2016, eLife.

[8]  A. Fauci.  An HIV Vaccine: Mapping Uncharted Territory. , 2016, JAMA.

[9]  S. Reed,et al.  In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. , 2016, Cytokine.

[10]  S. McCormack,et al.  Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study , 2016, PloS one.

[11]  Louise A. Carolan,et al.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine , 2016, Journal of Virology.

[12]  Louis B. Justement,et al.  Faculty Opinions recommendation of Class-switched memory B cells remodel BCRs within secondary germinal centers. , 2016 .

[13]  A. Bolhassani,et al.  Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.

[14]  Jerome H. Kim,et al.  Circulating HIV-Specific Interleukin-21(+)CD4(+) T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. , 2016, Immunity.

[15]  Jerome H. Kim,et al.  Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology , 2015, Cell.

[16]  P. Bruhns,et al.  Mouse and human FcR effector functions , 2015, Immunological reviews.

[17]  R. Coler,et al.  From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE , 2015, Clinical & translational immunology.

[18]  S. Crotty.  A brief history of T cell help to B cells , 2015, Nature Reviews Immunology.

[19]  U. Klein,et al.  Dynamics of B cells in germinal centres , 2015, Nature Reviews Immunology.

[20]  S. Kent,et al.  The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. , 2015, AIDS.

[21]  David F. Smith,et al.  The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites , 2015, Science Translational Medicine.

[22]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[23]  S. Crotty.  T follicular helper cell differentiation, function, and roles in disease. , 2014, Immunity.

[24]  G. Victora,et al.  Clonal and cellular dynamics in germinal centers. , 2014, Current opinion in immunology.

[25]  G. Alter,et al.  Dissecting the antibody constant region protective immune parameters in HIV infection , 2014 .

[26]  Jerome H. Kim,et al.  Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines , 2014, Science Translational Medicine.

[27]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[28]  S. Reed,et al.  Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen , 2014, PloS one.

[29]  C. Bailey-Kellogg,et al.  Divergent Antibody Subclass and Specificity Profiles but Not Protective HLA-B Alleles Are Associated with Variable Antibody Effector Function among HIV-1 Controllers , 2013, Journal of Virology.

[30]  Alessandro Sette,et al.  Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.

[31]  H. Liao,et al.  Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. , 2013, Journal of immunological methods.

[32]  P. Hraber,et al.  Neutralizing IgG at the Portal of Infection Mediates Protection against Vaginal Simian/Human Immunodeficiency Virus Challenge , 2013, Journal of Virology.

[33]  Laila N. Abudulai,et al.  Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection , 2013, Vaccines.

[34]  B. Gazzard,et al.  Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults , 2013, Clinical and Vaccine Immunology.

[35]  C. Bailey-Kellogg,et al.  High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.

[36]  Mario Roederer,et al.  Quality assurance for polychromatic flow cytometry using a suite of calibration beads , 2012, Nature Protocols.

[37]  Filippo Castiglione,et al.  How the Interval between Prime and Boost Injection Affects the Immune Response in a Computational Model of the Immune System , 2012, Comput. Math. Methods Medicine.

[38]  Magdalini Moutaftsi,et al.  Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140 , 2012, PloS one.

[39]  Jaranit Kaewkungwal,et al.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. , 2012, The Lancet. Infectious diseases.

[40]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[41]  S. Reed,et al.  GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. , 2012, The Journal of infectious diseases.

[42]  H. Ding,et al.  IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation , 2011, AIDS.

[43]  S. Jeffs,et al.  Phase I Randomised Clinical Trial of an HIV-1CN54, Clade C, Trimeric Envelope Vaccine Candidate Delivered Vaginally , 2011, PloS one.

[44]  M. Mulligan,et al.  Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. , 2011, The Journal of infectious diseases.

[45]  R. Obst,et al.  Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery , 2010, Proceedings of the National Academy of Sciences.

[46]  R. Ahmed,et al.  From vaccines to memory and back. , 2010, Immunity.

[47]  S. Bertholet,et al.  A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines , 2010, PloS one.

[48]  B. Walker,et al.  Immunology and the elusive AIDS vaccine , 2010, Nature.

[49]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[50]  E. C. Snow,et al.  Faculty Opinions recommendation of HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. , 2009 .

[51]  Susan Moir,et al.  B cells in HIV infection and disease , 2009, Nature Reviews Immunology.

[52]  T. Rispens,et al.  Immunoglobulin G4: an odd antibody , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[53]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[54]  Mario Roederer,et al.  Quality assurance for polychromatic flow cytometry , 2006, Nature Protocols.

[55]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[56]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Mascola,et al.  A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. , 2000 .

[58]  R. Belshe,et al.  Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1998, Vaccine.

[59]  Thomas Matthews,et al.  Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial , 1996, Annals of Internal Medicine.

[60]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[61]  Jerome H. Kim,et al.  Beyond RV144 Efficacy Results: An Update☆ , 2013 .

[62]  T. Rispens,et al.  Immunoglobulin G 4 : an odd antibody , 2011 .

[63]  J. Mascola,et al.  A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences. , 2000, Vaccine.

[64]  B. Graham,et al.  Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. , 1996, Annals of internal medicine.

[65]  K. Johnson.  An Update. , 1984, Journal of food protection.